These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 38530491)

  • 21. Impact of Uric Acid Levels on Kidney Disease Progression.
    Rincon-Choles H; Jolly SE; Arrigain S; Konig V; Schold JD; Nakhoul G; Navaneethan SD; Nally JV; Rothberg MB
    Am J Nephrol; 2017; 46(4):315-322. PubMed ID: 29032376
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of Febuxostat on Ambulatory Blood Pressure in Subjects With Hyperuricemia and Hypertension: A Phase 2 Randomized Placebo-Controlled Study.
    Gunawardhana L; McLean L; Punzi HA; Hunt B; Palmer RN; Whelton A; Feig DI
    J Am Heart Assoc; 2017 Nov; 6(11):. PubMed ID: 29102979
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Urate-Lowering Therapy in Moderate to Severe Chronic Kidney Disease.
    Levy G; Shi JM; Cheetham TC; Rashid N
    Perm J; 2018; 22():17-142. PubMed ID: 30201087
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level.
    Siu YP; Leung KT; Tong MK; Kwan TH
    Am J Kidney Dis; 2006 Jan; 47(1):51-9. PubMed ID: 16377385
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Febuxostat does not delay progression of carotid atherosclerosis in patients with asymptomatic hyperuricemia: A randomized, controlled trial.
    Tanaka A; Taguchi I; Teragawa H; Ishizaka N; Kanzaki Y; Tomiyama H; Sata M; Sezai A; Eguchi K; Kato T; Toyoda S; Ishibashi R; Kario K; Ishizu T; Ueda S; Maemura K; Higashi Y; Yamada H; Ohishi M; Yokote K; Murohara T; Oyama JI; Node K;
    PLoS Med; 2020 Apr; 17(4):e1003095. PubMed ID: 32320401
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The alkalizer citrate reduces serum uric Acid levels and improves renal function in hyperuricemic patients treated with the xanthine oxidase inhibitor allopurinol.
    Saito J; Matsuzawa Y; Ito H; Omura M; Ito Y; Yoshimura K; Yajima Y; Kino T; Nishikawa T
    Endocr Res; 2010; 35(4):145-54. PubMed ID: 20958145
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical efficacy and safety of topiroxostat in Japanese male hyperuricemic patients with or without gout: an exploratory, phase 2a, multicentre, randomized, double-blind, placebo-controlled study.
    Hosoya T; Sasaki T; Hashimoto H; Sakamoto R; Ohashi T
    J Clin Pharm Ther; 2016 Jun; 41(3):298-305. PubMed ID: 27079434
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The association between uric acid levels and renal function of CKD patients with hyperlipidemia: a sub-analysis of the ASUCA trial.
    Kuwabara Y; Yasuno S; Kasahara M; Ueshima K; Nakao K
    Clin Exp Nephrol; 2020 May; 24(5):420-426. PubMed ID: 31875936
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of uric acid-lowering therapy on the progression of chronic kidney disease: a systematic review and meta-analysis.
    Liu X; Zhai T; Ma R; Luo C; Wang H; Liu L
    Ren Fail; 2018 Nov; 40(1):289-297. PubMed ID: 29619870
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of Clinical Advantage between Topiroxostat and Febuxostat in Hemodialysis Patients.
    Mitsuboshi S; Yamada H; Nagai K; Okajima H
    Biol Pharm Bull; 2017; 40(9):1463-1467. PubMed ID: 28867729
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Time to target uric acid to retard CKD progression.
    Kumagai T; Ota T; Tamura Y; Chang WX; Shibata S; Uchida S
    Clin Exp Nephrol; 2017 Apr; 21(2):182-192. PubMed ID: 27339448
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Febuxostat Therapy for Patients With Stage 3 CKD and Asymptomatic Hyperuricemia: A Randomized Trial.
    Kimura K; Hosoya T; Uchida S; Inaba M; Makino H; Maruyama S; Ito S; Yamamoto T; Tomino Y; Ohno I; Shibagaki Y; Iimuro S; Imai N; Kuwabara M; Hayakawa H; Ohtsu H; Ohashi Y;
    Am J Kidney Dis; 2018 Dec; 72(6):798-810. PubMed ID: 30177485
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Uric acid is not associated with decline in renal function or time to renal replacement therapy initiation in a referred cohort of patients with Stage III, IV and V chronic kidney disease.
    Nacak H; van Diepen M; Qureshi AR; Carrero JJ; Stijnen T; Dekker FW; Evans M
    Nephrol Dial Transplant; 2015 Dec; 30(12):2039-45. PubMed ID: 26185050
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Reduction of uric acid levels with allopurinol treatment improves endothelial function in patients with chronic kidney disease.
    Yelken B; Caliskan Y; Gorgulu N; Altun I; Yilmaz A; Yazici H; Oflaz H; Yildiz A
    Clin Nephrol; 2012 Apr; 77(4):275-82. PubMed ID: 22445470
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparative effects of topiroxostat and febuxostat on arterial properties in hypertensive patients with hyperuricemia.
    Kario K; Nishizawa M; Kiuchi M; Kiyosue A; Tomita F; Ohtani H; Abe Y; Kuga H; Miyazaki S; Kasai T; Hongou M; Yasu T; Kuramochi J; Fukumoto Y; Hoshide S; Hisatome I
    J Clin Hypertens (Greenwich); 2021 Feb; 23(2):334-344. PubMed ID: 33400348
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Uric acid and incident chronic kidney disease in a large health check-up population in Taiwan.
    Wang S; Shu Z; Tao Q; Yu C; Zhan S; Li L
    Nephrology (Carlton); 2011 Nov; 16(8):767-76. PubMed ID: 21854506
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Topiroxostat versus allopurinol in patients with chronic heart failure complicated by hyperuricemia: A prospective, randomized, open-label, blinded-end-point clinical trial.
    Sakuma M; Toyoda S; Arikawa T; Koyabu Y; Kato T; Adachi T; Suwa H; Narita JI; Anraku K; Ishimura K; Yamauchi F; Sato Y; Inoue T
    PLoS One; 2022; 17(1):e0261445. PubMed ID: 35077456
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hyperuricemia is an independent predictive factor for left ventricular diastolic dysfunction in patients with chronic kidney disease.
    Gromadziński L; Januszko-Giergielewicz B; Pruszczyk P
    Adv Clin Exp Med; 2015; 24(1):47-54. PubMed ID: 25923086
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of uric acid on kidney function decline differ depending on baseline kidney function in type 2 diabetic patients.
    Hanai K; Tauchi E; Nishiwaki Y; Mori T; Yokoyama Y; Uchigata Y; Babazono T
    Nephrol Dial Transplant; 2019 Aug; 34(8):1328-1335. PubMed ID: 29860523
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Rationale and design of a multicenter randomized study for evaluating vascular function under uric acid control using the xanthine oxidase inhibitor, febuxostat: the PRIZE study.
    Oyama J; Tanaka A; Sato Y; Tomiyama H; Sata M; Ishizu T; Taguchi I; Kuroyanagi T; Teragawa H; Ishizaka N; Kanzaki Y; Ohishi M; Eguchi K; Higashi Y; Yamada H; Maemura K; Ako J; Bando YK; Ueda S; Inoue T; Murohara T; Node K;
    Cardiovasc Diabetol; 2016 Jun; 15():87. PubMed ID: 27317093
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.